12 Stocks Under $10 With High Upside Potential

Page 4 of 11

8. Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Share Price: $9.11

No. of Hedge Fund Holders: 40

Analyst Upside Potential: 86.61%

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a biotech company engaged in the discovery, development, and delivery of medicines to treat metabolic diseases. Amicus introduced the first and only approved oral precision medicine to treat Fabry disease, a clinical-stage treatment paradigm for Pompe disease.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted solid full-year 2024 financial results, with revenue reaching $528 million, up by 32% from a year ago. The company launched POMBILITI and OPFOLDA for late-onset Pompe disease, adding more than $70 million to revenue in their first year. The company’s precision medicine that treats Fabry disease, Galafold, achieved $458 million in revenue, driven by strong patient demand and market penetration.

Galafold’s continued penetration into the diagnosed untreated population will be a key driver of growth in 2025 and beyond. This positions Amicus to improve its profitability moving forward. The company is on track to reach $1 billion in total sales by 2028, with growing medicines with long commercial runways, financial strength, and a leverageable global infrastructure further supporting these objectives.

Page 4 of 11